- Home
- ENIC vs DNLI Comparison
ENIC vs DNLI Comparison
Compare ENIC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENIC
- DNLI
- Stock Information
- Founded
- ENIC 2016
- DNLI 2013
- Country
- ENIC Chile
- DNLI United States
- Employees
- ENIC N/A
- DNLI N/A
- Industry
- ENIC Electric Utilities: Central
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENIC Utilities
- DNLI Health Care
- Exchange
- ENIC Nasdaq
- DNLI Nasdaq
- Market Cap
- ENIC 4.0B
- DNLI 3.3B
- IPO Year
- ENIC N/A
- DNLI 2017
- Fundamental
- Price
- ENIC $2.98
- DNLI $23.04
- Analyst Decision
- ENIC Hold
- DNLI Strong Buy
- Analyst Count
- ENIC 1
- DNLI 13
- Target Price
- ENIC $3.90
- DNLI $38.91
- AVG Volume (30 Days)
- ENIC 487.2K
- DNLI 1.1M
- Earning Date
- ENIC 02-20-2025
- DNLI 02-25-2025
- Dividend Yield
- ENIC 7.18%
- DNLI N/A
- EPS Growth
- ENIC N/A
- DNLI N/A
- EPS
- ENIC 0.01
- DNLI N/A
- Revenue
- ENIC $5,287,759,941.00
- DNLI N/A
- Revenue This Year
- ENIC $16.01
- DNLI N/A
- Revenue Next Year
- ENIC N/A
- DNLI $651.24
- P/E Ratio
- ENIC $4.61
- DNLI N/A
- Revenue Growth
- ENIC 8.81
- DNLI 204.74
- 52 Week Low
- ENIC $2.51
- DNLI $14.56
- 52 Week High
- ENIC $3.24
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ENIC 60.00
- DNLI 56.23
- Support Level
- ENIC $2.88
- DNLI $18.52
- Resistance Level
- ENIC $2.97
- DNLI $22.37
- Average True Range (ATR)
- ENIC 0.06
- DNLI 1.30
- MACD
- ENIC 0.00
- DNLI 0.43
- Stochastic Oscillator
- ENIC 88.89
- DNLI 98.47
About ENIC Enel Chile S.A. (Each representing 50 shares of)
Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.